ABSTRACT:
Liposomes, spherical vesicles made of phospholipids and cholesterol, are a potential drug delivery mechanism due to their large size, hydrophobic and lipophilic properties. They exhibit high biocompatibility and stability, allowing for the encapsulation of both hydrophilic and lipophilic drugs. Their amphiphatic structure allows for regulated drug release within their compartments. Liposomes are used in treating various ailments like tumors and cancer. This comprehensive review of the Liposomal Drug Delivery System explores various aspects related to liposomes.
Cite this article:
Bharti Choudhary, Jitendra Banweer. A Review on Liposomes as Novel Drug Delivery System. Research Journal of Pharmacy and Technology. 2025;18(6):2864-7. doi: 10.52711/0974-360X.2025.00412
Cite(Electronic):
Bharti Choudhary, Jitendra Banweer. A Review on Liposomes as Novel Drug Delivery System. Research Journal of Pharmacy and Technology. 2025;18(6):2864-7. doi: 10.52711/0974-360X.2025.00412 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-6-65
REFERENCE:
1. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. Journal of Molecular Biology. 1964; Jan; 8(5): 660-IN10. doi.org/10.1016/s0022-2836(64)80115-7.
2. Lasic D. Novel applications of liposomes. Trends in Biotechnology [Internet]. 1998; Jul 1 [cited 2022 Mar 3]; 16(7): 307–21. doi.org/10.1016/s0167-7799(98)01220-7.
3. Mayer LD, Hope MJ, Cullis PR, Janoff AS. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1985; Jul 1;817(1):193–6. doi.org/10.1016/0005-2736(85)90084-7
4. Fujisawa T, Miyai H, Hironaka K, Tsukamoto T, Tahara K, Yuichi Tozuka, et al. Liposomal diclofenac eye drop formulations targeting the retina: Formulation stability improvement using surface modification of liposomes. International Journal of Pharmaceutics. 2012; Oct 1; 436(1-2): 564–7. doi.org/10.1016/j.ijpharm.2012.07.024.
5. Mishra H, Chauhan V, Kumar K, Teotia D. A comprehensive review on Liposomes: a novel drug delivery system. Journal of Drug Delivery and Therapeutics. 2018; Nov 25; 8(6): 400–4. doi.org/10.22270/jddt.v8i6.2071.
6. Kaur D, Kumar S. NIOSOMES: Present Scenario and Future Aspects. Journal of Drug Delivery and Therapeutics. 2018 Sep 6; 8(5): 35–43. doi.org/10.22270/jddt.v8i5.1886
7. Hong MS, Lim SJ, Lee MK, Kim YB, Kim CK. Prolonged blood circulation of methotrexate by modulation of liposomal composition. Drug delivery [Internet]. 2001; 8(4): 231–7. doi.org/10.1080/107175401317245912
8. Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharmaceutica Acta Helvetiae. 1995; Jul; 70(2): 95–111. doi.org/10.1016/0031-6865(95)00010-7
9. James ND, Coker RJ, Tomlinson D, Harris JRW, Gompels M, Pinching AJ, et al. Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi’s sarcoma in AIDS. Clinical Oncology. 1994 Jan;6(5):294–6. doi.org/10.1016/s0936-6555(05)80269-9.
10. Laouini A, Jaafar-Maalej C, Limayem-Blouza I, Sfar S, Charcosset C, Fessi H. Preparation, Characterization and Applications of Liposomes: State of the Art. Journal of Colloid Science and Biotechnology. 2012; Dec 1; 1(2): 147–68. doi.org/10.1166/jcsb.2012.1020.
11. Gregoriadis G, Davis C. Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cells. Biochemical and Biophysical Research Communications. 1979; Aug; 89(4): 1287–93. doi.org/10.1016/0006-291x(79)92148-x.
12. Ejiogu Deborah Chioma. Formulation And Evaluation Of Etodolac Niosomes By Modified Ether Injection Technique. Universal Journal of Pharmaceutical Research. 2016 Nov 15;1(1):1–6. doi.org/10.22270/ujpr.v1i1.r1
13. Ugochukwu AE. Preparation and Characterization of Tolterodine Tartrate Proniosomes. Universal Journal of Pharmaceutical Research. 2017 May 15;2(2):22–5. doi.org/10.22270/ujpr.v2i2.r1
14. Wasan KM, Lopez-Berestein G. The Past, Present, and Future Uses of Liposomes in Treating Infectious Diseases. Immunopharmacology and Immunotoxicology. 1995 Jan;17(1):1–15. doi.org/10.3109/08923979509052716
15. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews [Internet]. 2013 Jan [cited 2019 Mar 1];65(1):36–48. doi.org/10.1016/j.addr.2012.09.037.
16. Ellens H, Mayhew E, Rustum Y. Reversible depression of the reticuloendothelial system by liposomes. Biochimica et Biophysica Acta (BBA) - General Subjects. 1982; Feb 25; 714(3): 479–85. doi.org/10.1016/0304-4165(82)90157-x
17. Nekkanti, Vijaykumar and Kalepu, Sandeep. (2015). Recent Advances in Liposomal Drug Delivery: A Review. Pharmaceutical Nanotechnology. 3. 35-55. doi.org/10.2174/2211738503666150709173905
18. Barenholz Y (Chezy). Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release. 2012; Jun; 160(2): 117–34. doi.org/10.1016/j.jconrel.2012.03.020.